Sawyer & Company Inc Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Posted by on Mar 20th, 2023

Sawyer & Company Inc trimmed its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 4.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,861 shares of the biopharmaceutical company’s stock after selling 1,104 shares during the period. Sawyer & Company Inc’s holdings in Pfizer were worth $1,171,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Saxon Interests Inc. lifted its position in shares of Pfizer by 12.9% in the third quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 951 shares in the last quarter. Platte River Wealth Advisors LLC lifted its position in shares of Pfizer by 62.8% in the third quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock worth $556,000 after buying an additional 4,905 shares in the last quarter. Accuvest Global Advisors lifted its position in shares of Pfizer by 16.6% in the third quarter. Accuvest Global Advisors now owns 12,994 shares of the biopharmaceutical company’s stock worth $569,000 after buying an additional 1,848 shares in the last quarter. Ledyard National Bank lifted its position in shares of Pfizer by 0.5% in the third quarter. Ledyard National Bank now owns 364,223 shares of the biopharmaceutical company’s stock worth $15,938,000 after buying an additional 1,654 shares in the last quarter. Finally, Oak Asset Management LLC purchased a new stake in Pfizer during the third quarter valued at approximately $723,000. 67.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PFE. Wells Fargo & Company decreased their price objective on Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday. Atlantic Securities decreased their price objective on Pfizer from $50.00 to $46.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 1st. Barclays decreased their price objective on Pfizer from $49.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 1st. Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price objective on shares of Pfizer in a research report on Wednesday, February 1st. Finally, BMO Capital Markets decreased their price objective on Pfizer from $55.00 to $53.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 1st. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $50.38.

Pfizer Stock Down 0.7 %

Shares of NYSE:PFE opened at $40.10 on Monday. Pfizer Inc. has a 52-week low of $39.23 and a 52-week high of $56.32. The stock has a market cap of $225.33 billion, a P/E ratio of 7.32, a price-to-earnings-growth ratio of 1.34 and a beta of 0.64. The business’s 50 day moving average is $43.26 and its 200 day moving average is $46.04. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. During the same quarter in the prior year, the firm earned $1.08 earnings per share. Pfizer’s revenue was up 1.9% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 3.3 EPS for the current year.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Further Reading

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.